Fatemeh Sadat Mirzadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fatemeh Sadat Mirzadeh has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Hamidreza Hekmat
School of Medicine, Baharloo Hospital, International Campus, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir
3 shared publications - Zahra Vahabi
Cognitive Neurology, Dementia and Neuropsychiatry Research Center, Tehran University of Medical Sciences, Keshavarz Boulevard, Tehran, 1333715914, Iran
2 shared publications - Abolfazl Zendehdel
Internal Medicine Department, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Alireza Namazi Shabestari
Department of Geriatric Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication Amirmohammad Sharafi
Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
1 shared publication- Aziz Rasooli
Vice-Chancellor for Treatment Affairs, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 23 October 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (2) , 1-12
Safety and effectiveness of remdesivir in COVID-19 patients with liver dysfunction: a retrospective cohort study
Objective This study aimed to assess the safety and effectiveness of remdesivir in hospitalized COVID-19 patients with liver dysfunction. Methods A retrospective cohort study analyzed medical records of 268 patients hospitalized between 2019 and 2022 with COVID-19 and elevated liver enzymes (AST and ALT). Patients were divided into remdesivir (N = 134) and non-remdesivir (N = 134) groups. Outcomes assessed included in-hospital mortality, 30-day mortality, adverse events, time to clinical improvement, and time to discharge. Statistical analyses included logistic regression with significance at p < 0.05. Results A total of 268 patients (134 receiving remdesivir and 134 controls) were included. The remdesivir group was older, had lower oxygen saturation, and presented with more severe disease at baseline. Despite these differences, remdesivir use was associated with a significantly faster clinical recovery (adjusted β = − 2.18 days; 95% CI: − 4.206 to − 0.154; p = 0.035). In-hospital mortality was higher in the remdesivir group (10.45% vs. 7.46%), but this difference was not statistically significant after adjustment (OR 0.12; 95% CI: 0.001–8.390; p = 0.109). Remdesivir nearly doubled the risk of serious adverse events (OR 1.90; 95% CI: 0.988–3.656), although this did not reach statistical significance (p = 0.054). Independent predictors of death or major adverse events included ICU admission, elevated ALP, and concomitant use of certain medications. Conclusion Remdesivir appears safe in COVID-19 patients with liver dysfunction and significantly shortens time to clinical improvement without increasing mortality or serious adverse events.
- 23 October 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (2) , 1-12
Safety and effectiveness of remdesivir in COVID-19 patients with liver dysfunction: a retrospective cohort study
Objective This study aimed to assess the safety and effectiveness of remdesivir in hospitalized COVID-19 patients with liver dysfunction. Methods A retrospective cohort study analyzed medical records of 268 patients hospitalized between 2019 and 2022 with COVID-19 and elevated liver enzymes (AST and ALT). Patients were divided into remdesivir (N = 134) and non-remdesivir (N = 134) groups. Outcomes assessed included in-hospital mortality, 30-day mortality, adverse events, time to clinical improvement, and time to discharge. Statistical analyses included logistic regression with significance at p < 0.05. Results A total of 268 patients (134 receiving remdesivir and 134 controls) were included. The remdesivir group was older, had lower oxygen saturation, and presented with more severe disease at baseline. Despite these differences, remdesivir use was associated with a significantly faster clinical recovery (adjusted β = − 2.18 days; 95% CI: − 4.206 to − 0.154; p = 0.035). In-hospital mortality was higher in the remdesivir group (10.45% vs. 7.46%), but this difference was not statistically significant after adjustment (OR 0.12; 95% CI: 0.001–8.390; p = 0.109). Remdesivir nearly doubled the risk of serious adverse events (OR 1.90; 95% CI: 0.988–3.656), although this did not reach statistical significance (p = 0.054). Independent predictors of death or major adverse events included ICU admission, elevated ALP, and concomitant use of certain medications. Conclusion Remdesivir appears safe in COVID-19 patients with liver dysfunction and significantly shortens time to clinical improvement without increasing mortality or serious adverse events.
- Open Access
- 1 March 2025
- Published by InkVista Publishing House in Iranian Journal of Health Insurance
- Vol. 7 (4) , 227-236
Exploring the Complex Challenges of Heart Failure: Healthcare Costs, Access, and Social Factors in Iran
Introduction: Heart failure and cardiovascular diseases pose significant health challenges in Iran and beyond, straining healthcare systems and impacting patients' quality of life due to costs and access issues. Understanding the management challenges of these conditions is essential for improving health outcomes. Methods: This study explores the challenges of heart ...
- 1 March 2025
- Published by InkVista Publishing House in Iranian Journal of Health Insurance
- Vol. 7 (4) , 227-236
Open AccessExploring the Complex Challenges of Heart Failure: Healthcare Costs, Access, and Social Factors in Iran
Introduction: Heart failure and cardiovascular diseases pose significant health challenges in Iran and beyond, straining healthcare systems and impacting patients' quality of life due to costs and access issues. Understanding the management challenges of these conditions is essential for improving health outcomes. Methods: This study explores the challenges of heart ...
- Open Access
- 23 December 2024
- Published by Springer Nature in BMC Geriatrics
- Vol. 24 (1) , 1034
Happiness, sleep quality, and self-care ability among community-dwelling older adults in Tehran, 2023
Background Population aging presents a significant challenge that requires comprehensive planning. Limited research has been done on the interconnections between happiness, sleep, and self-care in older adults. This study aimed to determine the Happiness, Sleep quality, and Self-care ability among community-dwelling older adults in Tehran, 2023. Methods This is a cross-sectional study. We selected 306 eligible, community-dwelling older adults through multistage sampling. Participants were recruited from comprehensive health service centers. We employed three assessments: the Oxford Happiness Inventory (OHI), the Pittsburgh Sleep Quality Index (PSQI), and the Self-Care Ability Scale for the Elderly (SASE). Data analysis was conducted using SPSS version 27, the Spearman correlation test, and univariate and multivariate linear regression analyses. Results The results indicated that 58% of older adults were male, 67.6% were married, and 44% were retired. A multivariate linear regression analysis revealed a significant association with happiness. Self-care ability had a negative impact (beta = -1.50, p < 0.001), while sleep quality had a positive effect (beta = 0.50, p < 0.001). Conclusion Self-care and sleep quality are associated with overall happiness. Policymakers and planners should prioritize happiness enhancement by addressing its relationship with sleep and self-care practices.
- 23 December 2024
- Published by Springer Nature in BMC Geriatrics
- Vol. 24 (1) , 1034
Open AccessHappiness, sleep quality, and self-care ability among community-dwelling older adults in Tehran, 2023
Background Population aging presents a significant challenge that requires comprehensive planning. Limited research has been done on the interconnections between happiness, sleep, and self-care in older adults. This study aimed to determine the Happiness, Sleep quality, and Self-care ability among community-dwelling older adults in Tehran, 2023. Methods This is a cross-sectional study. We selected 306 eligible, community-dwelling older adults through multistage sampling. Participants were recruited from comprehensive health service centers. We employed three assessments: the Oxford Happiness Inventory (OHI), the Pittsburgh Sleep Quality Index (PSQI), and the Self-Care Ability Scale for the Elderly (SASE). Data analysis was conducted using SPSS version 27, the Spearman correlation test, and univariate and multivariate linear regression analyses. Results The results indicated that 58% of older adults were male, 67.6% were married, and 44% were retired. A multivariate linear regression analysis revealed a significant association with happiness. Self-care ability had a negative impact (beta = -1.50, p < 0.001), while sleep quality had a positive effect (beta = 0.50, p < 0.001). Conclusion Self-care and sleep quality are associated with overall happiness. Policymakers and planners should prioritize happiness enhancement by addressing its relationship with sleep and self-care practices.
- 2 December 2024
- Published by Springer Nature in Ageing International
- Vol. 50 (1) , 1-13
Risk Factors for Frailty in Iranian Older Adult Outpatients: a Cross-Sectional Study
- 2 December 2024
- Published by Springer Nature in Ageing International
- Vol. 50 (1) , 1-13
Risk Factors for Frailty in Iranian Older Adult Outpatients: a Cross-Sectional Study
- Open Access
- 10 October 2023
- Published by Wiley in Journal of Immunology Research
- Vol. 2023, 1-11
A Review of Antibiotic Efficacy in COVID-19 Control
Severe acute respiratory disease is associated with chronic secondary infections that exacerbate symptoms and mortality. So far, many drugs have been introduced to treat this disease, none of which effectively control the coronavirus. Numerous studies have shown that mitochondria, as the center of cell biogenesis, are vulnerable to drugs, especially antibiotics. Antibiotics were widely prescribed during the early phase of the pandemic. We performed a literature review to assess the reasons, evidence, and practices on the use of antibiotics in coronavirus disease 2019 (COVID-19) in- and outpatients. The current research found widespread usage of antibiotics, mostly in an empirical context, among COVID-19 hospitalized patients. The effectiveness of this approach has not been established. Given the high death rate linked with secondary infections in COVID-19 patients and the developing antimicrobial resistance, further study is urgently needed to identify the most appropriate rationale for antibiotic therapy in these patients.
- 10 October 2023
- Published by Wiley in Journal of Immunology Research
- Vol. 2023, 1-11
Open AccessA Review of Antibiotic Efficacy in COVID-19 Control
Severe acute respiratory disease is associated with chronic secondary infections that exacerbate symptoms and mortality. So far, many drugs have been introduced to treat this disease, none of which effectively control the coronavirus. Numerous studies have shown that mitochondria, as the center of cell biogenesis, are vulnerable to drugs, especially antibiotics. Antibiotics were widely prescribed during the early phase of the pandemic. We performed a literature review to assess the reasons, evidence, and practices on the use of antibiotics in coronavirus disease 2019 (COVID-19) in- and outpatients. The current research found widespread usage of antibiotics, mostly in an empirical context, among COVID-19 hospitalized patients. The effectiveness of this approach has not been established. Given the high death rate linked with secondary infections in COVID-19 patients and the developing antimicrobial resistance, further study is urgently needed to identify the most appropriate rationale for antibiotic therapy in these patients.
- Open Access
- 25 June 2022
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 14 (3) , 201-204
Diffuse alveolar hemorrhage; An under-diagnosed and rare complication of glycoprotein IIb/IIIa inhibitors
Glycoprotein IIb/IIIa inhibitors play a key role in the treatment of patients who have acute coronary syndromes and undergone percutaneous coronary intervention. However, its serious complication is diffused alveolar hemorrhage. A 73-year-old diabetic woman presented with chest pain and dynamic ST elevation in ECG and positive troponin. She had occlusion in two coronary arteries and underwent percutaneous coronary intervention. The eptifibatide was administered. After hours, she showed respiratory symptoms, as well as drop of blood pressure and hemoglobin. All differential diagnoses suggested for her clinical presentation were evaluated, and finally, on the sixth day diffuse alveolar hemorrhage was diagnosed. Although respiratory symptoms such as hemoptysis and dyspnea may occur as complications of pulmonary edema and/or pneumonia, assumed clinical suspicion for pulmonary hemorrhage leading to early detection of it. Moreover, there is no definitive guideline for decreased bleeding complications and treatment of alveolar hemorrhage caused by glycoprotein IIb/IIIa receptor inhibitors.
- 25 June 2022
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 14 (3) , 201-204
Open AccessDiffuse alveolar hemorrhage; An under-diagnosed and rare complication of glycoprotein IIb/IIIa inhibitors
Glycoprotein IIb/IIIa inhibitors play a key role in the treatment of patients who have acute coronary syndromes and undergone percutaneous coronary intervention. However, its serious complication is diffused alveolar hemorrhage. A 73-year-old diabetic woman presented with chest pain and dynamic ST elevation in ECG and positive troponin. She had occlusion in two coronary arteries and underwent percutaneous coronary intervention. The eptifibatide was administered. After hours, she showed respiratory symptoms, as well as drop of blood pressure and hemoglobin. All differential diagnoses suggested for her clinical presentation were evaluated, and finally, on the sixth day diffuse alveolar hemorrhage was diagnosed. Although respiratory symptoms such as hemoptysis and dyspnea may occur as complications of pulmonary edema and/or pneumonia, assumed clinical suspicion for pulmonary hemorrhage leading to early detection of it. Moreover, there is no definitive guideline for decreased bleeding complications and treatment of alveolar hemorrhage caused by glycoprotein IIb/IIIa receptor inhibitors.
- 13 August 2020
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 69 (4) , 173-179
Comparison effectiveness of acute coronary syndrome treatments on geriatric function
- 13 August 2020
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 69 (4) , 173-179
Comparison effectiveness of acute coronary syndrome treatments on geriatric function